Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: erippetoe	1/12/2026 12:53:14 PM
	of 63332

SRPT *Preliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025* *Preliminary ELEVIDYS net product revenue totaled $110.4 million for the fourth quarter and $898.7 million for full-year 2025* *Preliminary PMO net product revenues totaled $259.2 million for the fourth quarter and $965.6 million for full-year 2025* *Preliminary year-end 2025 cash, cash equivalents, restricted cash and investments balance of approximately $953.8 million* stocktitan.net Additionally, from etrade... 12:47 PM EST, 01/12/2026 (MT Newswires) -- Sarepta Therapeutics (SRPT) reported preliminary net product revenues of $369.6 million in Q4 and $1.86 billion in 2025. Analysts surveyed by FactSet forecast $379.7 million in Q4 and $2.12 billion in 2025. As of Dec. 31, preliminary cash, cash equivalents, restricted cash and investments totaled $953.8 million, the company said Monday in a statement. Sarepta shares fell 14% in recent Monday trading. Price: 20.41, Change: -3.42, Percent Change: -14.35

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next